WHO_HTM_TB_2009_420_5

Three times weekly dosing throughout therapy [2(HRZE)3/4(HR)3] may be
used as another alternative to Recommendation 2.1, provided that every
dose is directly observed and the patient is NOT living with HIV or living in
an HIV-prevalent setting.